Thermo Fisher Scientific Inc. recently announced the availability of a fully integrated solution for polymer-based drug implant development and production using hot melt extrusion (HME).
The system is being called the Thermo Scientific Pharma mini implant line. It is built around the mini HME twin-screw micro compounder and provides drug developers, process manufacturing scientists and engineers with a fast production process.
The goal is to improve product quality while also maximizing operator safety and mitigating contamination risks.
"With a single subcutaneous injection, advanced drug implants can release a therapeutic substance that can provide patients with improved drug compliance, effective disease treatment or controlled hormonal regulation for weeks or even months," Hanna Granö-Fabritius, senior business director of material characterization for Thermo Fisher Scientific, said in a statement. "Pharmaceutical manufacturers are seeking fast, reliable solutions for continuous production of novel drug delivery systems. Our new, automated implant line offers a hot melt extrusion solution designed to minimize formulation development time."
Thermo Fisher Scientific is a premier company serving the science industry with 55,000 employees around the world. Its mission is to accelerate life sciences research.